Stratagene Shares Dive 8.6 Percent After Judge Trebles Damages in Invitrogen IP-Infringement Verdict | GenomeWeb
NEW YORK (GenomeWeb News) — Shares in Stratagene were down 8.6 percent, or $.59, at $6.24 in mid-afternoon trading today after a judge ordered the company to pay $16 million in damages to Invitrogen for willfully infringing one of its patents.
 
Separately today, investment bank Robert W. Baird downgraded Stratagene’s stock to ‘Underperform’ from ‘Neutral.’
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.